Inventiva reports preliminary 2023 fiscal year financial Inf

Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million2, and long-term deposit...

Related Keywords

Tianqing , Zhejiang , China , Japan , France , Israel , Daix , Bourgogne , South Korea , Ukraine , United States , New York , Paris , France General , Boston , Massachusetts , Russia , Chinese , French , Pascaline Clerc , Julia Cailleteau , Aude Lepreux , Sino Biopharm , Chia Tai Tianqing Pharmaceutical Group Co Ltd , Exchange Commission , Data Monitoring Committee , Brunswick Group , Corporate Affairs , Products Administration , Health Care Conference , Nasdaq , Market Program , Hepalys Pharma Inc , Patricial Bank , European Investment Bank , Suspected Unexpected Serious Adverse Reaction , Long Island City , Euronext Paris , Chief Executive Officer , Hepalys Pharma , Data Monitoring , Investigational New Drug , Medical Products Administration , At The Market Program , Hepalys License , Informed Consent Form , Patient First Visit , Annual Health Care Conference , Paris Hepatology Conference , Annual Conference Liver Connect , Nasdaq Global Market , Roquet Montegon , Private Securities Litigation Reform Act , New Drug Application , Universal Registration Document , Des March , Annual Report , Half Year Report , Markets ,